Vaccine Completion or Hospital Platforms First? A Country-Level Typology of Child Pneumonia Intervention Priorities in 204 Countries

Background Global child pneumonia strategy increasingly asks whether marginal resources should go to completing vaccine programmes or to hospital platform investments. The answer cannot be uniform across countries. We operationalised this question as a country-level priority typology for 204 countries, treating the vaccine policy dimension, coverage with pneumococcal conjugate vaccine (PCV), Haemophilus influenzae type b (Hib) vaccine, and diphtheria-tetanus-pertussis vaccine (DTP), as a first-order input to classification rather than an after-the-fact check. Methods We combined Global Burden of Disease Study 2023 estimates of deaths from 29 pneumonia-relevant pathogens in ages 0–19 years for 204 countries in 2023, each pathogen assigned to a dominant intervention channel (vaccine-reachable, mixed, platform-sensitive) under previously published rules, with WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) for PCV3, Hib3, DTP3 and BCG, and with WHO vaccine-introduction records. An EPI coverage index (mean of PCV3 and Hib3) summarised conjugate-vaccine programme strength. Countries were classified by declared thresholds into low-burden (<500 deaths), vaccine-priority (vaccine-channel share ≥40% and EPI index <80%), platform-priority (platform share ≥50%), or mixed-transitional. Vaccine residual space was computed as vaccine-channel deaths multiplied by the coverage gap. Robustness of the typology was verified by bootstrap resampling of the 204 countries (500 replicates; all four types perfectly stable, mean Jaccard 1.00, because classification is a deterministic per-country rule) and by ±5 percentage-point sensitivity on all three declared thresholds, which reclassified 4–11 countries (2.0–5.4%) per threshold (Supplementary Text S9, Tables S9–S10). Findings In 2023 the 29 pathogens accounted for 964,615 deaths: 45.7% vaccine-reachable, 13.1% mixed and 41.1% platform-sensitive. Thirty-two vaccine-priority countries carried 51.8% of all deaths; within them, 20 urgent-stratum countries (EPI index <60%) carried 209,807 deaths and 12 completion-stage countries (60-80%) carried 289,607. Ten vaccine-priority countries, including China, had not introduced PCV nationally, representing introduction space rather than within-programme coverage gaps. Forty-seven countries with DTP3 coverage below 80% carried 62.6% of global pertussis deaths. Eighteen platform-priority countries carried 7.8% of deaths; the same two pathogens (Klebsiella pneumoniae, Pseudomonas aeruginosa) led the platform channel across high-burden settings. Across the 2019-2023 pandemic window, the largest single-country share movements pushed platform shares down as COVID-19 entered the vaccine channel, but across the full set of 82 countries with at least 500 deaths the platform share rose in 61 countries and fell in 21 (median +1.8 percentage points), with the largest increases in South Africa (+8.1) and Lesotho (+8.0). Conclusions Whether vaccines or platforms come first is an empirical country attribute, not a global verdict. The 204-country typology and accompanying dataset offer a concrete starting point for allocating the next increment of child pneumonia resources.